Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Impact of Individual Antiretroviral Drugs on the Risk of Myocardial Infarction in Human Immunodeficiency Virus–Infected Patients

Impact of Individual Antiretroviral Drugs on the Risk of Myocardial Infarction in Human... ORIGINAL INVESTIGATION Impact of Individual Antiretroviral Drugs on the Risk of Myocardial Infarction in Human Immunodeficiency Virus–Infected Patients A Case-Control Study Nested Within the French Hospital Database on HIV ANRS Cohort CO4 Sylvie Lang, MSc; Murielle Mary-Krause, PhD; Laurent Cotte, MD; Jacques Gilquin, MD; Marialuisa Partisani, MD; Anne Simon, MD; Franck Boccara, MD, PhD; Dominique Costagliola, PhD; for the Clinical Epidemiology Group of the French Hospital Database on HIV Background: The role of exposure to specific antiret- Results: Short-term/recent exposure to abacavir was as- roviral drugs on risk of myocardial infarction in human sociated with an increased risk of MI in the overall sample immunodeficiency virus (HIV)–infected patients is de- (odds ratios [ORs], 2.01; 95% confidence interval [CI], 1.11- bated in the literature. 3.64) but not in the subset of matched cases and controls (81%) who did not use cocaine or intravenous drugs (1.27; Methods: To assess whether we confirmed the associa- 0.64-2.49). Cumulative exposure to all PIs except saquina- tion between exposure to abacavir and risk of myocar- vir was associated with an increased risk of MI significant dial infarction (MI) and to estimate the impact of expo- for amprenavir/fosamprenavir with or without ritonavir sure to other nucleoside http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Internal Medicine American Medical Association

Impact of Individual Antiretroviral Drugs on the Risk of Myocardial Infarction in Human Immunodeficiency Virus–Infected Patients

Download PDF
11 pages

Loading next page...
 
/lp/american-medical-association/impact-of-individual-antiretroviral-drugs-on-the-risk-of-myocardial-vep50rMF94

References (36)

Publisher
American Medical Association
Copyright
Copyright 2010 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6106
eISSN
2168-6114
DOI
10.1001/archinternmed.2010.197
pmid
20660842
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL INVESTIGATION Impact of Individual Antiretroviral Drugs on the Risk of Myocardial Infarction in Human Immunodeficiency Virus–Infected Patients A Case-Control Study Nested Within the French Hospital Database on HIV ANRS Cohort CO4 Sylvie Lang, MSc; Murielle Mary-Krause, PhD; Laurent Cotte, MD; Jacques Gilquin, MD; Marialuisa Partisani, MD; Anne Simon, MD; Franck Boccara, MD, PhD; Dominique Costagliola, PhD; for the Clinical Epidemiology Group of the French Hospital Database on HIV Background: The role of exposure to specific antiret- Results: Short-term/recent exposure to abacavir was as- roviral drugs on risk of myocardial infarction in human sociated with an increased risk of MI in the overall sample immunodeficiency virus (HIV)–infected patients is de- (odds ratios [ORs], 2.01; 95% confidence interval [CI], 1.11- bated in the literature. 3.64) but not in the subset of matched cases and controls (81%) who did not use cocaine or intravenous drugs (1.27; Methods: To assess whether we confirmed the associa- 0.64-2.49). Cumulative exposure to all PIs except saquina- tion between exposure to abacavir and risk of myocar- vir was associated with an increased risk of MI significant dial infarction (MI) and to estimate the impact of expo- for amprenavir/fosamprenavir with or without ritonavir sure to other nucleoside

Journal

JAMA Internal Medicine – American Medical Association

Published: Jul 26, 2010

There are no references for this article.